Inventor · disambiguated record
Sophie-Dorothee Clas
Also filed as: CLAS SOPHIE D · CLAS SOPHIE-DOROTHEE
7 granted patents·2 pending applications·49 citations·filing 1992–2013
83Inventor score
Files withMERCK & CO INC3CLAS SOPHIE-DOROTHEE2MERCK FROSST CANADA INC2LOWCHOL SCIENT INC1MERCK SHARP & DOHME1
Top patents by PatentIndex Score
9 records- 0176US6150534ASynthesis of 4-[5-substituted or unsubstituted phenyl)-3-substituted-1H-pyrazol-1-yl]benzenesulfonamidesMERCK FROSST CANADA INC·Filed 2000·Granted Nov 21, 2000·7 cites·8 claims
- 0275US6441002B1Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinylMERCK & CO INC·Filed 2000·Granted Aug 27, 2002·4 cites·14 claims
- 0370US6232472B1Synthesis of 4-[(5-substituted phenyl)-3-substituted-1H-pyrazol-1-yl]benzenesulfonamideMERCK FROSST CANADA INC·Filed 2000·Granted May 15, 2001·4 cites·2 claims
- 0466US6740666B2Substituted 8-arylquinoline phosphodiesterase-4 inhibitorsMERCK & CO INC·Filed 2001·Granted May 25, 2004·5 cites·4 claims
- 0560US7560559B2Polymorphic form of montelukast sodiumMERCK & CO INC·Filed 2004·Granted Jul 14, 2009·5 cites·10 claims
- 0655US5427777AIngestible polymeric phosphonium salts, composition thereof and method of treating hypercholesterolemiaLOWCHOL SCIENT INC·Filed 1992·Granted Jun 27, 1995·24 cites·17 claims
- 0749US2015166520A1Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infectionMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 0834US8552193B2Alternative forms of the phosphodiesterase-4 inhibitor N-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamideCLAS SOPHIE-DOROTHEE·Filed 2010·Granted Oct 8, 2013·0 cites·3 claims
- 0934US2008119509A1Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-CarboxyamideCLAS SOPHIE-DOROTHEE·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →